A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer

Completed · Phase 3

Conditions studied: Breast Cancer, Lymph Node Mapping, Sentinel Lymph Node Biopsy

In brief

This is a prospective, open label, multicenter, non-inferiority within-patient study to determine the effectiveness of IC2000 (Indocyanine Green (ICG) for Injection) and the SPY Portable Handheld Imaging System (SPY-PHI) as an intraoperative fluorescence visualization tool, in the visual identification of lymphatic vessels and lymph nodes (LNs) during lymphatic mapping and sentinel lymph node biopsy (SLNB) procedures as confirmed by Technitium99m (Tc99m) and Gamma Probe.

Key facts

Study ID

NCT03200704

Run by

Novadaq Technologies ULC, now a part of Stryker

People needed

152

Starts

2019-01-04

Expected to finish

2020-09-28

Last updated by the study team

2023-09-21

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Be 18 years of age or older
• Subjects with American Cancer Society Clinical Stage 0 Ductal Carcinoma in Situ (DCIS) (Stage 0, Tis, N0, M0), IA (T1*, N0, M0), IB ((T0, N1mi, M0) or T1*, N1mi, M0)) or Stage IIA (T0, N1**M0, or T1, N1**, M0 or T2, N0, M0)1 breast cancer undergoing surgery to remove tumor draining LNs.
• Where:
• Tis = Ductal carcinoma in situ
• T0 = No evidence of primary tumor
• T1 = Tumor ≤ 20 mm in greatest diameter
• T1* = Includes T1mi
• T2 = Tumor >20 mm but ≤ 50 mm in greatest diameter
• N0 = No regional lymph node metastasisq1'
• N1 = Metastasis to movable ipsilateral level I, II axillary LNs
• N1** = T0 and T1 tumors with nodal micro-metastasis only are excluded from Stage IIA and are classified Stage IB.
• mi = Micro-metastasis
• M0 = Disease has not metastasized from Stage IIA and are classified Stage IB.
• M0= No evidence of metastasis
• mi= Micrometastasis
• Subjects with clinically negative nodal status (N0) with or without neoadjuvant chemotherapy
• Subjects with negative metastatic involvement (M0)
• Subjects of child-bearing potential must not be pregnant or lactating and must have a negative pregnancy test at Baseline
• Have signed an approved informed consent form for the study
• Be willing to comply with the protocol

You may not qualify if…

• Have had prior axillary surgery or ipsilateral radiation in the breast(s) that is planned for the procedure
• Advanced breast cancer subjects with stage IIB, III and IV
• Known allergy or history of adverse reaction to ICG, iodine or iodine dyes
• Subjects who have participated in another investigational study within 30 days prior to surgery
• Pregnant or lactating subject
• Subjects who, in the Investigator's opinion, have any medical condition that makes the subject a poor candidate for

Where it is running

• Arizona Center for Cancer Care — Scottsdale, Arizona, United States
• MedStar Georgetown University Hospital — Washington D.C., District of Columbia, United States
• Baptist MD Anderson Cancer Center — Jacksonville, Florida, United States
• Methodist Dallas Medical Center — Dallas, Texas, United States
• Inova Health System — Alexandria, Virginia, United States
• Fraser Health Authority — Port Moody, British Columbia, Canada
• CHU de Québec-Université Laval (Hôpital du Saint-Sacrement) — Québec, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.